NASDAQ:ENGN

enGene Q4 2025 Earnings Results & Report

enGene logo
$1.74 -0.03 (-1.42%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

enGene missed analyst earnings expectations in its Q4 2025 results, released December 22, 2025. The company reported EPS of -$0.73 versus the -$0.55 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Conference Call
4:00 PM ET

enGene EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.55
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

enGene's Q4 2026 earnings is estimated for Tuesday, December 22, 2026, based on past reporting schedules, with a conference call scheduled on Friday, December 18, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

enGene Q4 2025 Earnings FAQ

enGene (NASDAQ:ENGN) reported earnings of -$0.73 per share for Q4 2025, missing the consensus estimate of -$0.55. The report was announced on Monday, December 22, 2025.

enGene's next earnings date is estimated for Tuesday, December 22, 2026. MarketBeat tracks confirmed and estimated earnings dates for enGene on the company's earnings history page.

enGene Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
enGene (NASDAQ:ENGN) Upgraded at Leerink Partners
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile